Trial Profile
Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs Thiotepa (Primary) ; Antineoplastics
- Indications Osteosarcoma
- Focus Biomarker; Therapeutic Use
- Acronyms OSII-TTP
- 12 Dec 2019 Primary endpoint (Estimate the overall survival rate) has not been met.
- 12 Dec 2019 Results assessing efficacy and tolerance of high-dose thiotepa (HDTp) after standard chemotherapy (SCT) in patients with relapsed osteosarcoma published in the European Journal of Cancer
- 16 May 2019 Status changed from active, no longer recruiting to completed.